Stay updated on ARV-471 Combo vs Letrozole Combo in Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the ARV-471 Combo vs Letrozole Combo in Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ARV-471 Combo vs Letrozole Combo in Breast Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.1%
    Check dated 2025-01-19T20:09:28.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The study has been updated to include 40 locations and a new type of intervention, while the previous version had 41 locations and included a site in São Paulo, Brazil.
    Difference
    1%
    Check dated 2025-01-12T17:03:23.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    25 days ago
    No Change Detected
  5. Check
    32 days ago
    No Change Detected
  6. Check
    40 days ago
    Change Detected
    Summary
    The website has been updated from version v2.13.2 to v2.13.3.
    Difference
    0.1%
    Check dated 2024-12-14T12:27:27.000Z thumbnail image
  7. Check
    47 days ago
    Change Detected
    Summary
    The website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study and includes a reference to the Contacts and Locations section.
    Difference
    2%
    Check dated 2024-12-07T10:40:31.000Z thumbnail image
  8. Check
    61 days ago
    Change Detected
    Summary
    The website has added a 'Show less' feature while removing detailed options related to participant groups, interventions, and various data fields for downloads.
    Difference
    3%
    Check dated 2024-11-23T04:23:53.000Z thumbnail image
  9. Check
    68 days ago
    Change Detected
    Summary
    A new study titled 'A Study of Vepdegestrant (ARV-471, PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer (VERITAC-3)' has been added, replacing the previous version of the study, which has been deleted.
    Difference
    4%
    Check dated 2024-11-15T22:42:27.000Z thumbnail image

Stay in the know with updates to ARV-471 Combo vs Letrozole Combo in Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ARV-471 Combo vs Letrozole Combo in Breast Cancer Clinical Trial page.